Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1411 to 1425 of 1876 results for do not dos

  1. Should women having a surgical abortion up to and including 10 +0  weeks' gestation have anti-D prophylaxis if they are RhD (or D) negative?

    laboratories usually follow the same processes for managing anti-D as they do for managing whole transfusion systems. This is...

    Research recommendation
    Published
    8 November 2019

  2. In women with type 1 diabetes who are planning to become pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring intermittent capillary blood glucose monitoring?

    continuous glucose monitoring for pregnant women who are on insulin therapy but do not have type 1 diabetes because they wanted to...

    Research recommendation
    Published
    22 January 2021

  3. In women with type 1 diabetes who are already pregnant, what is the most effective method of glucose monitoring to improve maternal and baby outcomes: continuous glucose monitoring flash glucose monitoring?

    continuous glucose monitoring for pregnant women who are on insulin therapy but do not have type 1 diabetes because they wanted to...

    Research recommendation
    Published
    22 January 2021

  4. Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?

    professional offering the procedure, such as a cardiologist, would usually do this. For people with other contraindications to...

    Research recommendation
    Published
    10 February 2020

  5. What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4 alone for people with hypothyroidism whose symptoms have not responded sufficiently to T4 alone? Does DiO2 polymorphism affect the response to combination therapy with T4 and T3?

    levothyroxine as thyroid hormone replacement and small subgroups of people who do not feel well on levothyroxine are sometimes offered...

    Research recommendation
    Published
    10 February 2020

  6. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA729

  7. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.

    Technology appraisal guidance
    Published
    27 August 2003
    View recommendations

    Sections for TA64

  8. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)

    Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

    Technology appraisal guidance
    Published
    31 March 2021
    View recommendations

    Sections for TA687

  9. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    8 August 2018
    View recommendations

    Sections for TA537

  10. Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    31 January 2018
    View recommendations

    Sections for TA502

  11. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA414

  12. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

    Evidence-based recommendations on pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA569

  13. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

    HealthTech guidance
    Published
    29 August 2012
    View recommendations

    Sections for HTG291

  14. What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury?

    professional offering the procedure, such as a cardiologist, would usually do this. For people with other contraindications to...

    Research recommendation
    Published
    10 February 2020

  15. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

    Medtech innovation briefing
    Published
    21 April 2021